Dual-Labeled E-AB Platform for Continuous, Real-Time Monitoring of Small Molecules
Corrects for sensor drift in flowing whole bloodBaseline drift corrections for more than 20 hours
Monitoring of narrow therapeutic index drugs Monitoring specific molecules in complex matrices such as tissue culture Can be used in sensors for the detection of a range of small molecule drugs and metabolites as well as for proteins Real-time and continuous monitoring of specific molecules in undiluted whole blood
To combat this, researchers at UC Santa Barbara have created a dual-reporter correction to enhance the performance of electrochemical aptamer-based sensors in whole blood. This sensor architecture paves a way to real-time and continuous metabolic, pharmacokinetic and drug-response measurements. The approach largely eliminates the drift observed for both cocaine and aminoglycoside-detecting E-AB sensors, reducing drift of order 25% - 30% to less than 2% over many hours of continuous operation in flowing, undiluted whole blood.
Background Historically, several methods have been employed to quantify small molecules and biomarkers in diluted or undiluted blood. However, these methods are very cumbersome and some of them only work for diluted whole blood. Further, they usually fail when applied for real-time, continuous monitoring of the target of interests in whole blood. While such a technology could, for example, provide maximal information about drug levels in blood throughout the day and enable sensitive, real-time dose adjustments and optimal treatment decisions for the patients, achieving this has proven difficult as the design and preparation molecular sensors that can be used in whole blood for real-time and long-term measurements has proven very challenging. Additional Technologies by these Inventors Tech ID/UC Case 27069/2016-99M-0 Related Cases 2016-99M-0
USA
